Home | GSK US
Company We are GSK As a focused biopharma company, we discover, develop and deliver medicines and vaccines to create value for patients and shareholders. We aim to positively impact the health of
Related Topics:
Reverse Stock Split
GSK to invest $30 billion in R&D and Manufacturing in the United
GSK plc (LSE/NYSE: GSK) today announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years.
Careers | GSK US
Careers We are GSK At GSK, we unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful,
GSK''s RSV vaccine, AREXVY, approved in US for expanded age
GSK continues to advance regulatory submissions for its RSV vaccine across multiple geographies to expand availability and support long-term growth objectives. About AREXVY
Vaccines | GSK US
The vaccines in our portfolio have been helping to protect people from serious disease for well over 100 years, with our Marietta, PA site dedicated to smallpox vaccine production since 1882. Today, our
Products
Unfortunately, we cannot provide comprehensive information about our products here, in compliance with regulations. If you are a healthcare professional, you can access more product information on
Search jobs
Life at GSK We are transforming our culture to create an environment where individuals and teams are inspired to be ambitious for patients
Company | GSK US
GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs.
GSK presents positive data for B7-H4-targeted ADC in gynecological
Promising efficacy and safety profile supports start of five pivotal phase III trials in 2026 GSK plc (LSE/NYSE: GSK) today announced positive findings from its global phase I BEHOLD-1